Comparable stake leader
Soleus Private Equity Fund III, L.P.
SEC ownership of Nuvectis Pharma, Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001875558.
Disclosed value leader
Ron Bentsur
Comparable rows
1/50
Latest evidence
04 Aug 2026
- Public ticker
- NVCT on Nasdaq
- Parsed ownership sources
-
13D/G, 3/4/5, and 13F
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
Soleus Private Equity Fund III, L.P.
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
1 of 50
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
Soleus Private Equity Fund III, L.P.
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
04 Aug 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001875558
- Issuer location
- Fort Lee, NJ
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Nuvectis Pharma, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Soleus Private Equity Fun...
Disclosed value leader
Ron Bentsur
Comparable rows
1/50
Latest evidence
04 Aug 2026
13D/G
3/4/5
13F
Lead comparable stake: 5.1%
49 rows are not safely comparable across share classes.
13D/G row: Soleus Private Equity Fund III, L.P.
Showing 1-8 of 50 holder rows.
Quick read
Soleus Private Equity Fund III, L.P. leads the comparable SEC ownership view at 5.1%.
1 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Soleus Private Equity Fund III, L.P.'s linked filing trail.
Comparable ownership
Top 1
Soleus Private Equity Fund III, L.P.
5.1%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Soleus Private Equity Fund III, L.P. |
13D/G
Soleus Capital Management, L.P.
|
5.1%
Reported 13D/G
· 04 Aug 2026
|
$30,389,563
1,648,024 shares
|
$0 | 04 Aug 2026 |
| Ron Bentsur |
3/4/5
Chairman & CEO, Director, 10%+ Owner
|
—
denominator unverified
|
$73,768,480
3,688,424 shares
|
+$278,600 | 30 Jun 2026 |
| Marlio Charles Mosseri |
3/4/5
10%+ Owner
|
—
denominator unverified
|
$59,223,123
3,295,897 shares
|
+$916,000 | 30 Jun 2026 |
| TANG CAPITAL MANAGEMENT LLC |
13F
Company
|
—
denominator unverified
|
$28,504,500
1,550,000 shares
|
— | 30 Jun 2026 |
| BlackRock, Inc. |
13F
Company
|
—
denominator unverified
|
$18,413,632
1,001,285 shares
|
— | 30 Jun 2026 |
| PERCEPTIVE ADVISORS LLC |
13F
Company
|
—
denominator unverified
|
$18,390,000
1,000,000 shares
|
— | 30 Jun 2026 |
| Soleus Capital Management, L.P. |
13F
Company
|
—
denominator unverified
|
$18,390,000
1,000,000 shares
|
— | 30 Jun 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC |
13F
Company
|
—
denominator unverified
|
$16,044,944
872,482 shares
|
— | 30 Jun 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to buying over the last 12 months. Net value: +$1,334,110.
Buys
$1,334,110
Insiders: 4
Sells
$0
Insiders: 0
Net
+$1,334,110
Shares: +91,500
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 91,500
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 62,500 | 0 | $1,166,000 | $0 | +$1,166,000 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 29,000 | 0 | $168,110 | $0 | +$168,110 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-10 of 10 reporting-owner rows connected to Nuvectis Pharma, Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
10
Largest Forms 3/4/5 holder
Ron Bentsur
Net 12M change
+$1.33M
Full value: +$1,334,110 · USD · 12-month changeLatest report
03 Aug 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Ron Bentsur | Chairman & CEO, Director, 10%+ Owner | $73,768,480 | +$278,600 | +0.38% | Filing P/S | 30 Jun 2026 |
| Marlio Charles Mosseri | 10%+ Owner | $59,223,123 | +$916,000 | +1.6% | Mixed | 30 Jun 2026 |
| Enrique Poradosu | Chief Science & Business Off | $13,637,527 | Mixed | 06 Jan 2026 | ||
| Shay Shemesh | Chief Dev. & Ops. Officer | $13,537,484 | Mixed | 06 Jan 2026 | ||
| Michael J. Carson | Vice President, Finance | $4,231,870 | Mixed | 03 Aug 2026 | ||
| Kenneth Hoberman | Director | $1,299,722 | Mixed | 11 Jun 2026 | ||
| Matthew L. Kaplan | Director | $1,234,944 | +$64,240 | +5.5% | Mixed | 11 Jun 2026 |
| James F. Oliviero III | Director | $949,460 | Mixed | 11 Jun 2026 | ||
| Juan Sanchez | Director | $879,634 | +$75,270 | +9.4% | Mixed | 11 Jun 2026 |
| Uri Ben-Or | Int. Principal Financial Off. | $283,471 | Mixed | 08 Feb 2022 |
Recent insider transactions for Nuvectis Pharma, Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Michael J. Carson | NVCT | Common Stock | Award | 15% | 30,000 | 230,118 | 03 Aug 2026 | Direct | ||
| Marlio Charles Mosseri | NVCT | Common Stock | Purchase | 1.59% | $916,000 | $18.32 | 50,000 | 3,186,576 | 30 Jun 2026 | By Emerald Hill Ventures SARL SPF. |
| Ron Bentsur | NVCT | Common Stock | Purchase | 0.34% | $250,000 | $20.00 | 12,500 | 3,688,424 | 30 Jun 2026 | Direct |
| Kenneth Hoberman | NVCT | Common Stock | Award | 26.3% | 35,000 | 168,140 | 11 Jun 2026 | Direct | ||
| James F. Oliviero III | NVCT | Common Stock | Award | 39.8% | 35,000 | 122,828 | 11 Jun 2026 | Direct | ||
| Juan Sanchez | NVCT | Common Stock | Award | 44.6% | 35,000 | 113,380 | 11 Jun 2026 | Direct | ||
| Matthew L. Kaplan | NVCT | Common Stock | Award | 28% | 35,000 | 159,760 | 11 Jun 2026 | Direct | ||
| Shay Shemesh | NVCT | Common Stock | Award | 9.13% | 150,000 | 1,793,068 | 06 Jan 2026 | Direct | ||
| Ron Bentsur | NVCT | Common Stock | Award | 4.25% | 150,000 | 3,675,924 | 06 Jan 2026 | Direct | ||
| Enrique Poradosu | NVCT | Common Stock | Award | 9.06% | 150,000 | 1,806,319 | 06 Jan 2026 | Direct | ||
| Michael J. Carson | NVCT | Common Stock | Award | 44% | 61,200 | 200,118 | 06 Jan 2026 | Direct | ||
| Juan Sanchez | NVCT | Common Stock | Purchase | 20% | $75,270 | $5.79 | 13,000 | 78,150 | 05 Nov 2025 | Direct |
| Matthew L. Kaplan | NVCT | Common Stock | Purchase | 9.67% | $64,240 | $5.84 | 11,000 | 124,760 | 05 Nov 2025 | Direct |
| Ron Bentsur | NVCT | Common Stock | Purchase | 0.14% | $28,600 | $5.72 | 5,000 | 3,525,924 | 05 Nov 2025 | Direct |
* marks a reported price that did not pass the local price check.